Improving Diagnosis and Treatment for Patients With Rectal Cancer

ConditionGI Cancer
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age16-99
SponsorImperial College London

About this trial

The cancer stage information from scans guides pre-operative treatment and the type of surgery offered. The investigators are studying whether a new Magnetic Resonance Imaging (MRI) staging method can improve the accuracy of prognosis for patients diagnosed with rectal cancer. The investigators will provide consultant radiologists with the know-how to report MRI scans using this new method and compare this with the existing method. This study will test this by comparing how accurately the old versus new method predict the outcomes of patients. The existing method relies on radiologists determining if tumour has spread through the bowel wall or not and whether there are suspected malignant lymph nodes. The new method looks for tumour spread into the veins and whether or not there are tumour deposits. Our previous research has shown that the new method is much more accurate at predicting prognosis, but this finding needs to be verified by a larger multicentre study.

The investigators are also studying the patient journey, so the investigators can better understand patients' experiences and the impact that treatments have on their quality of life. The investigators wish to understand if improvements in the accuracy of prognosis from scans could change treatment decisions in future. The investigators will also compare the radiology scan prediction of prognostic factors by looking carefully at the tumour specimens.

Eligibility criteria

Qualifiers

Have a rectal cancer proven on biopsy or subsequent surgery

Sites able to submit anonymised MRI staging scans, pathology and imaging reports for central review

Aged 16 years or over

Disqualifiers

Have irresectable metastatic disease at time of initial staging

Undergoing palliative treatment for Rectal Cancer

Have a biopsy-proven rectal malignancy which is not adenocarcinoma

Are contraindicated for MRI staging

Trial design

Treatments tested in this trial

  • mrTDV

Treatment groups

438 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Imperial College London

Lead sponsor

NHS England

Collaborator

Pelican Cancer Foundation

Collaborator